Labeling has been updated to include specific information about the adaptations of Spikevax to target new SARS-CoV-2 variants, including the use of adapted vaccines like the bivalent Original/Omicron BA.1 and BA.4-5.
Keeping the labeling up-to-date ensures that healthcare professionals and the public are informed about the most effective vaccine preparations against current variants of COVID-19, ultimately enhancing public health responses.
Regulatory teams should integrate the new labeling information into their literature surveillance processes to ensure compliance and accurate communication surrounding Spikevax usage.
Regulatory Intelligence Lead
Review in the next regulatory intelligence cycle.
Regulatory teams should integrate the new labeling information into their literature surveillance processes to ensure compliance and accurate communication surrounding Spikevax usage.
The European Medicines Agency (EMA) has updated the labeling for Spikevax, detailing its adaptations targeting the most recent strains of SARS-CoV-2, including the bivalent Original/Omicron BA.1 and BA.4-5 vaccines. This update reflects the continuous evolution of the virus and aims to maintain vaccine efficacy and protection against COVID-19.
What changed: Labeling has been updated to include specific information about the adaptations of Spikevax to target new SARS-CoV-2 variants, including the use of adapted vaccines like the bivalent Original/Omicron BA.1 and BA.4-5.
Why it matters: Keeping the labeling up-to-date ensures that healthcare professionals and the public are informed about the most effective vaccine preparations against current variants of COVID-19, ultimately enhancing public health responses.
Practical implication: Regulatory teams should integrate the new labeling information into their literature surveillance processes to ensure compliance and accurate communication surrounding Spikevax usage.
Published from the regulator source ingestion pipeline after PV impact triage.
Regulatory requirements for daratumumab will need to be reviewed in light of the orphan designation status granted by the EMA.
Regulatory Intelligence teams must monitor updates regarding the ongoing CHMP evaluation and potential implications for existing marketing authorizations.
Update all internal and external communications, labels, and marketing materials to reflect the new product name, Svariya, instead of Rivaroxaban Koanaa.
Regulatory Intelligence Leads must incorporate the new reporting requirements and deadlines into their monitoring activities for affected products.
